{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:59:13Z","timestamp":1781510353298,"version":"3.54.1"},"reference-count":39,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Yonsei University College of Medicine","award":["6-2024-0051"],"award-info":[{"award-number":["6-2024-0051"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: There is little evidence available regarding the long-term tumor response after transarterial radioembolization (TARE) for hepatocellular carcinoma (HCC). Aim: To identify preprocedural predictive factors for achieving a 5-year complete response (CR) following TARE in patients with HCC. Methods: This retrospective study included 37 patients with treatment-na\u00efve HCC who underwent TARE between January 2016 and December 2019 and were followed for at least 5 years. Tumor characteristics\u2014including maximum diameter, number of main lesions, presence of satellite nodules, and portal vein thrombosis\u2014were evaluated using preprocedural liver dynamic magnetic resonance imaging. Treatment response was assessed according to the modified Response Evaluation Criteria in Solid Tumors. Multivariate logistic regression analyses were performed to identify factors associated with tumor response following TARE. Results: Thirty-seven patients (median age, 64 years) were categorized into two groups: (1) the CR group (n = 9), consisting of patients without tumor recurrence for 5 years and without additional treatment; and (2) the non-CR group (n = 28), consisting of patients who required additional treatment because of residual or recurrent viable tumors. Tumors in the non-CR group had significantly larger diameters compared with those in the CR group (9.8 cm vs. 5.9 cm, p = 0.006). In multivariable analysis, a tumor diameter &gt; 7 cm was the only factor significantly associated with tumor recurrence (odds ratio = 21.277, p = 0.010). Portal vein thrombosis did not reach statistical significance (odds ratio = 9.779, p = 0.063). Conclusions: Tumor diameter &gt; 7 cm is a significant predictor of tumor recurrence within 5 years after TARE for HCC. This finding may support a more individualized post-TARE management approach, potentially allowing clinicians to avoid overtreatment and adopt a watchful waiting strategy for selected patients.<\/jats:p>","DOI":"10.3390\/diagnostics15182297","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:27:12Z","timestamp":1757500032000},"page":"2297","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of Preprocedural Factors Associated with 5-Year Complete Response After Transarterial Radioembolization in Patients with Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-9730","authenticated-orcid":false,"given":"June","family":"Park","sequence":"first","affiliation":[{"name":"Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Kyu","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"},{"name":"Department of Radiology, Yongin Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Yongin 16995, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungsoo","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiology, Yongin Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Yongin 16995, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Hye","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Yongin Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Yongin 16995, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"111948","DOI":"10.1016\/j.ejrad.2025.111948","article-title":"Prediction of treatment response and outcome of transarterial chemoembolization in patients with hepatocellular carcinoma using artificial intelligence: A systematic review of efficacy","volume":"184","author":"Keshavarz","year":"2025","journal-title":"Eur. J. Radiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/JHC.S50359","article-title":"Transarterial radioembolization for hepatocellular carcinoma: A review","volume":"25","author":"Sacco","year":"2016","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","article-title":"Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): A single-centre, single-arm study","volume":"7","author":"Kim","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1148\/radiol.2018171768","article-title":"Radiation segmentectomy: Potential curative therapy for early hepatocellular carcinoma","volume":"287","author":"Lewandowski","year":"2018","journal-title":"Radiology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_9","unstructured":"American College of Radiology (2024, March 01). Liver Imaging Reporting and Data System Version 2018. Published 2018. Available online: https:\/\/www.acr.org\/Clinical-Resources\/Clinical-Tools-and-Reference\/Reporting-and-Data-Systems\/LI-RADS."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/01.RVI.0000227234.81718.EB","article-title":"Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization","volume":"17","author":"Deng","year":"2006","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.1007\/s00330-022-08732-4","article-title":"Assessment of HCC response to yttrium-90 radioembolization with gadoxetate disodium MRI: Correlation with histopathology","volume":"32","author":"Gnerre","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.17998\/jlc.2022.01.16","article-title":"Radioembolization for hepatocellular carcinoma: What clinicians need to know","volume":"22","author":"Choi","year":"2022","journal-title":"J. Liver Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jvir.2023.06.023","article-title":"Early prediction of response of hepatocellular carcinoma to yttrium-90 radiation segmentectomy using a machine learning MR imaging radiomic approach","volume":"34","author":"Marinelli","year":"2023","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00330-023-10045-z","article-title":"Early post-treatment MRI predicts long-term hepatocellular carcinoma response to radiation segmentectomy","volume":"34","author":"Stocker","year":"2024","journal-title":"Eur. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2967\/jnumed.121.263147","article-title":"Long-term outcomes of transarterial radioembolization for large single hepatocellular carcinoma: A comparison to resection","volume":"63","author":"Kim","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_16","first-page":"185","article-title":"Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection","volume":"3","author":"She","year":"2014","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1007\/s00259-025-07185-3","article-title":"Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinoma","volume":"8","author":"Muglia","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4143\/crt.2014.013","article-title":"Which patients should we follow up beyond 5 years after definitive therapy for localized renal cell carcinoma?","volume":"47","author":"Lee","year":"2015","journal-title":"Cancer Res. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jtcvs.2012.01.078","article-title":"Five-year survival does not equal cure in non\u2013small cell lung cancer: A Surveillance, Epidemiology, and End Results\u2013based analysis of variables affecting 10-to 18-year survival","volume":"143","author":"Hubbard","year":"2012","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jhep.2019.09.028","article-title":"Novel patient-derived preclinical models of liver cancer","volume":"72","author":"Bresnahan","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Sun, H., Yang, H., and Mao, Y. (2023). Personalized treatment for hepatocellular carcinoma in the era of targeted medicine and bioengineering. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1150151"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1148\/radiol.2018181494","article-title":"Liver Imaging Reporting and Data System (LI-RADS) version 2018: Imaging of hepatocellular carcinoma in at-risk patients","volume":"289","author":"Chernyak","year":"2018","journal-title":"Radiology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.gastro.2009.06.003","article-title":"A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma","volume":"137","author":"Roayaie","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Moon, S., Kim, G.M., Won, J.Y., Kwon, J.H., Park, J., Han, K., Kim, M.-D., Kim, H.C., Kim, D.K., and Choi, J.Y. (2024). Clinical course of patients with hepatocellular carcinoma who experienced radiologic complete response after radioembolization. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1349632"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jvir.2024.01.031","article-title":"Tumor size and watershed area correlate with incomplete treatment and tumor progression after selective radioembolization for hepatocellular carcinoma","volume":"35","author":"Yu","year":"2024","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.5009\/gnl16001","article-title":"Predictive factors for complete response and recurrence after transarterial chemoembolization in hepatocellular carcinoma","volume":"11","author":"Jeong","year":"2017","journal-title":"Gut Liver"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.15403\/jgld.2014.1121.274.fcr","article-title":"Predictive Factors of Tumor Recurrence and Survival in Patients with Hepatocellular Carcinoma treated with Transarterial Chemoembolization","volume":"27","author":"Cerban","year":"2018","journal-title":"J. Gastrointestin Liver Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/curroncol28010095","article-title":"Predictors of complete response in patients with hepatocellular carcinoma treated with trans-arterial radioembolization","volume":"28","author":"Kim","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.hbpd.2021.12.004","article-title":"Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review","volume":"21","author":"Tao","year":"2022","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/ans.12803","article-title":"Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis","volume":"86","author":"Leng","year":"2016","journal-title":"ANZ J. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.hpb.2017.04.016","article-title":"Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: A systematic review and meta-analysis","volume":"19","author":"Silva","year":"2017","journal-title":"HPB"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Weng, Z., Ertle, J., Zheng, S., Lauenstein, T., Mueller, S., Bockisch, A., Gerken, G., Yang, D., Schlaak, J.F., and Hoshida, Y. (2013). A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0082225"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lopez-Lopez, V., Miura, K., Kuemmerli, C., Capel, A., Eshmuminov, D., Ferreras, D., Baroja-Mazo, A., Cascales-Campos, P., Jim\u00e9nez-Mascu\u00f1\u00e1n, M.I., and Pons, J.A. (2023). Selecting the appropriate downstaging and bridging therapies for hepatocellular carcinoma: What is the role of transarterial radioembolization? A pooled analysis. Cancers, 15.","DOI":"10.3390\/cancers15072122"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3350\/cmh.2017.0004","article-title":"Radioembolization for the treatment of hepatocellular carcinoma","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1109\/TRPMS.2018.2878934","article-title":"Comparison of radiomics models built through machine learning in a multicentric context with independent testing: Identical data, similar algorithms, different methodologies","volume":"3","author":"Upadhaya","year":"2018","journal-title":"IEEE Trans. Radiat. Plasma Med. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2967\/jnumed.117.200501","article-title":"Responsible radiomics research for faster clinical translation","volume":"59","author":"Zwanenburg","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ebiom.2019.08.054","article-title":"Multicentric validation of radiomics findings: Challenges and opportunities","volume":"47","author":"Hatt","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.radonc.2018.10.027","article-title":"Vulnerabilities of radiomic signature development: The need for safeguards","volume":"130","author":"Welch","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-0258(20000229)19:4<441::AID-SIM349>3.0.CO;2-N","article-title":"Sample size considerations for the evaluation of prognostic factors in survival analysis","volume":"19","author":"Schmoor","year":"2000","journal-title":"Stat. Med."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/18\/2297\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:43:10Z","timestamp":1760035390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/18\/2297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":39,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["diagnostics15182297"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15182297","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}